Iovance Biotherapeutics reported record Q3 2026 earnings, marking a financial milestone for the cell-therapy developer. The result comes alongside recent trial

Iovance Biotherapeutics reported record Q3 2026 earnings, marking a financial milestone for the cell-therapy developer. The result comes alongside recent trial updates in lung cancer and melanoma, signaling continued momentum in its oncology pipeline.